Lisdexamfetamine dimesylate

Drug ingredientActive Shortage

CAS 608137-33-3

This drug ingredient is in active FDA shortage. At least one manufacturer cannot meet demand.

US productionNot reported

Import value, 2024$872M

Top sourceSwitzerland 44%

This chemical is not on EPA’s Toxic Substances Control Act inventory, the list behind EPA’s production survey.

Why supply is unknown

Production is reported production, not a complete census of factories. Import value and source-country shares describe a shared customs category, not a separate chemical measurement.

Where It Comes From

Customs basis: HS 292429 · basket

These shares come from HS customs code 292429, which covers 203 tracked chemicals in total. They estimate the category's origin mix, not this chemical specifically.

Source Countries

Country of origin for US imports, from Census customs data (2024).

CH 44%SwitzerlandCN 19%ChinaIN 12%IndiaJP 9%JapanIE 6%Ireland

Taiwan
United Kingdom
El Salvador
Colombia
Ukraine
Brazil
Guatemala
Belgium
Netherlands
Turkey
Sweden
Greece
Canada
Israel
New Zealand
Latvia
Lithuania
Finland
Slovakia
Australia
Hong Kong
Czech Republic
Armenia
Poland

32 FDA-registered drug labelers

Alvogen Inc.

American Health Packaging

American Pacific Corporation

Amneal Pharmaceuticals LLC

Apotex Corp.

AvKARE

Azurity Pharmaceuticals, Inc.

Bryant Ranch Prepack

Camber Pharmaceuticals, Inc.

Cambrex Charles City, Inc

Chattem Chemicals, Inc.

Curia New York, Inc.

Elite Laboratories, Inc.

Euticals, Inc.

Granules India Limited

Granules Pharmaceuticals Inc.

Hikma Pharmaceuticals USA Inc.

Lannett Company, Inc.

Mylan Pharmaceuticals Inc.

Noramco, LLC

Novadoz Pharmaceuticals LLC

Patheon Manufacturing Services LLC

Patheon Pharmaceuticals Inc.

Rhodes Pharmaceuticals

S&B Pharma LLC dba Norac Pharma

Sandoz Inc

Solco Healthcare US,LLC

SpecGx LLC

Sun Pharmaceutical Industries, Inc.

Takeda Pharmaceuticals America, Inc.

Teva Pharmaceuticals, Inc.

Veranova, L.P.

Why It Matters

Sectors

Health

Downstream Uses

Appears in 3 drug and cosmetic product listings (FDA).

•Lisdexamfetamine Dimesylate
•Arynta
•Vyvanse

FDA Shortage Status

Whether any manufacturer currently reports this drug as in shortage on the FDA Drug Shortages database. "Active Shortage" means at least one presentation has status "current."

Active Shortage

Shortage History

Rows group FDA shortage filings by drug product. Each manufacturer makes its own FDA shortage filing, so one product can carry several reports at once: Available, Limited Availability, Unavailable or to be discontinued.

Current shortage
Lisdexamfetamine Dimesylate Capsule
Shortage listed since July 14, 2023
Manufacturer reports: 1 unavailable, 1 limited, 4 available
Current shortage
Lisdexamfetamine Dimesylate Tablet, Chewable
Shortage listed since July 14, 2023
Manufacturer reports: 1 available

See all current drug shortages

Chemical Identity

CAS608137-33-3

PubChem CID11597697

DTXSIDDTXSID60209653

FormulaC17H33N3O7S2

Mol. Weight455.6 g/mol

SMILESCC(CC1=CC=CC=C1)NC(=O)C(CCCCN)N.CS(=O)(=O)O.CS(=O)(=O)O

Data Sources

PubChem · compound 11597697Retrieved 2026-04-07
FDA National Drug Code directoryRetrieved 2026-04-25
FDA Drug ShortagesRetrieved 2026-10-04
US Census international tradeReporting year: 2024 · Retrieved 2026-10-04

← Back to Dashboard ← Back to Health

Brief citations

Lisdexamfetamine dimesylate (CAS 608137-33-3) https://chemicalindependence.com/chemical/608137-33-3/ PubChem: 11597697. Retrieved 2026-04-07. https://pubchem.ncbi.nlm.nih.gov/compound/11597697 FDA National Drug Code directory: CAS 608137-33-3. Retrieved 2026-04-25. https://open.fda.gov/data/ndc/ FDA Drug Shortages: CAS 608137-33-3. Retrieved 2026-10-04. https://www.accessdata.fda.gov/scripts/drugshortages/ US Census international trade: HS 292429 for CAS 608137-33-3. Reporting year: 2024. https://usatrade.census.gov/